Dogged by set­backs and an air of cri­sis, Alex­ion Phar­ma opts to re­struc­ture, slash­ing staff

Not much has been go­ing right for Alex­ion Phar­ma $ALXN over the past few months. Its CEO and CFO left un­der a cloud dur­ing an in­ves­ti­ga­tion of dodgy sales prac­tices. Its at­tempt to di­ver­si­fy through an $8.4 bil­lion ac­qui­si­tion of Synage­va stalled. And its lead drug, a high pro­file Soliris, has at­tract­ed com­pe­ti­tion look­ing to un­der­cut its steep price as sales have be­gun to de­cline.

What a great time to re­struc­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER